Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ALVAC-HIV and Bivalent Subtype C gp120 Vaccines in Healthy, HIV-uninfected Adults
NCT03284710Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Prophylactic Vaccines, Viral Vectors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of ALVAC-HIV, bivalent subtype C gp120/MF59 in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Jun 2017; status: completed.
02
Drugs
ALVAC-HIVbivalent subtype C gp120/MF59
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03284710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284710.